Huadong Medicine Buys Rights of ImmunoPharma Technology's Drug for Leukemia, Lymphoma

MT Newswires Live08-05

Chinese pharmaceutical company Huadong Medicine's (SHE:000963) unit, Huadong Medicine (Hangzhou), agreed to acquire the exclusive commercialization rights of Beijing ImmunoPharma Technology's CD19-targeted autologous CAR-T candidate product IM19 chimeric antigen receptor T cell injection, according to the company's filing on the Shenzhen Stock Exchange.

Huadong Medicine will receive an initial payment of 125 million yuan and registration and sales milestone payments of up to 950 million yuan.

The drug is undergoing clinical trials as a treatment for relapsed or refractory diffuse large B cell lymphoma, acute B cell lymphoblastic leukemia and mantle cell lymphoma, the Sunday filing noted.

Shares of the company rose more than 2% in recent trade.

Price (RMB): Â¥29.76, Change: Â¥+0.85, Percent Change: +2.94%

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2457679917?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2024-08-05 12:11","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2457679917","market":"nz","top_or_hot":-1,"title":"Huadong Medicine Buys Rights of ImmunoPharma Technology's Drug for Leukemia, Lymphoma","media":"MT Newswires Live","content":"<html><body><p> Chinese pharmaceutical company Huadong Medicine's (SHE:000963) unit, Huadong Medicine (Hangzhou), agreed to acquire the exclusive commercialization rights of Beijing ImmunoPharma Technology's CD19-targeted autologous CAR-T candidate product IM19 chimeric antigen receptor T cell injection, according to the company's filing on the Shenzhen Stock Exchange.</p><p>Huadong Medicine will receive an initial payment of 125 million yuan and registration and sales milestone payments of up to 950 million yuan.</p><p>The drug is undergoing clinical trials as a treatment for relapsed or refractory diffuse large B cell lymphoma, acute B cell lymphoblastic leukemia and mantle cell lymphoma, the Sunday filing noted.</p><p>Shares of the company rose more than 2% in recent trade.</p><p>Price (RMB): Â¥29.76, Change: Â¥+0.85, Percent Change: +2.94%</p></body></html>","source":"mtnewswires_news","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Huadong Medicine Buys Rights of ImmunoPharma Technology's Drug for Leukemia, Lymphoma</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nHuadong Medicine Buys Rights of ImmunoPharma Technology's Drug for Leukemia, Lymphoma\n</h2>\n\n<h4 class=\"meta\">\n\n\n2024-08-05 12:11 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.mtnewswires.com/><strong>MT Newswires Live</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Chinese pharmaceutical company Huadong Medicine's (SHE:000963) unit, Huadong Medicine (Hangzhou), agreed to acquire the exclusive commercialization rights of Beijing ImmunoPharma Technology's CD19-...</p>\n\n<a href=\"https://www.mtnewswires.com/\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"000963","symbol_name":"华东医药","start_time":0,"source_url":"https://www.mtnewswires.com/","article_id":"2457679917","we_media_id":"1092851196","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2457679917","pubTimestamp":1722831099,"sourceInfo":{"source_id":"mtnewswires_news","name":"MT Newswires"},"weMediaInfo":{"media_name":"MT Newswires Live","introduction":"The most recognized names in North America, Europe and Asia rely on MT Newswires to power their applications. Better news, better service, better price.","home_visible":1,"id":"1092851196","head_image":"https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e"},"summary":"Chinese pharmaceutical company Huadong Medicine's  unit, Huadong Medicine , agreed to acquire the exclusive commercialization rights of Beijing ImmunoPharma Technology's CD19-targeted autologous CAR-T candidate product IM19 chimeric antigen receptor T cell injection, according to the company's filing on the Shenzhen Stock Exchange.Huadong Medicine will receive an initial payment of 125 million yuan and registration and sales milestone payments of up to 950 million yuan.The drug is undergoing clinical trials as a treatment for relapsed or refractory diffuse large B cell lymphoma, acute B cell lymphoblastic leukemia and mantle cell lymphoma, the Sunday filing noted.Shares of the company rose more than 2% in recent trade.Price : 29.76, Change: +0.85, Percent Change: +2.94%","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"000963":"华东医药","BK0196":"行业龙头","BK0209":"零售","BK0183":"MSCI概念","BK0175":"白马股","LU1969619763.USD":"EASTSPRING INV CHINA A SHARES GROWTH \"A\" (USD) ACC","LU2328871848.SGD":"Eastspring Investments - China A Shares Growth AS SGD","BK0132":"高送转概念","BK0188":"融资融券","BK0187":"一线龙头"},"translate_title":"华东医药购买ImmunoPharma Technology治疗白血病、淋巴瘤药物的权利","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"000963":0.9},"content_text":"Chinese pharmaceutical company Huadong Medicine's (SHE:000963) unit, Huadong Medicine (Hangzhou), agreed to acquire the exclusive commercialization rights of Beijing ImmunoPharma Technology's CD19-targeted autologous CAR-T candidate product IM19 chimeric antigen receptor T cell injection, according to the company's filing on the Shenzhen Stock Exchange.Huadong Medicine will receive an initial payment of 125 million yuan and registration and sales milestone payments of up to 950 million yuan.The drug is undergoing clinical trials as a treatment for relapsed or refractory diffuse large B cell lymphoma, acute B cell lymphoblastic leukemia and mantle cell lymphoma, the Sunday filing noted.Shares of the company rose more than 2% in recent trade.Price (RMB): Â¥29.76, Change: Â¥+0.85, Percent Change: +2.94%","kind":null,"is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":1},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.28.3","shortVersion":"4.28.3","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2457679917"}